Overview

Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery Patients

Status:
Withdrawn
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, pharmacokinetic and the pharmacodynamic effects of escalating doses of MTR105 while weaning from bypass in a hypotensive population of cardiac surgery patients.
Phase:
Phase 2
Details
Lead Sponsor:
Meditor Pharmaceuticals Ltd.